HypertensionLOD-HTANCT02022618
Target Organ Damage and Polymorphisms Vav-2 and Vav-3 in Hypertensive Subjects
An observational study of Hypertension, run by Fundacion para la Investigacion y Formacion en Ciencias de la Salud at 1 site in Spain.
Trial summary
Objectives: To analyze the influence on the presence of target organ damage renal, cardiac and vascular of peripheral and central blood pressure, retinal vessels caliber, oxidative stress and polymorphisms of genes VAV-2-3 in hypertensive subjects. Methodology: A cross- sectional design we will performed . Read more about this study
- Who is it for?
- Ages 20 to 80 years
- Conditions the study is for
- Hypertension
- How many people
- 454 participants
- Where
- 1 siteSpain
- Study dates
- Oct 2013to Mar 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Population: 486 hypertensive patients (20-80 years) will be assessed with all tests recommended in 2013 European guidelines of hypertension
Who may be able to join
- Subjects diagnosed of essential hypertension and age between 20-80 years.
Who cannot join
- Participants who do not sign the consent written informed
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Target Organ Damage and Blood Pressure, Retinal Vessels, Oxidative Stress and Polymorphisms Vav-2 and Vav-3 in Hypertensive Subjects (LOD-Hypertension)
Objectives: To analyze the influence on the presence of target organ damage renal, cardiac and vascular of peripheral and central blood pressure, retinal vessels caliber, oxidative stress and polymorphisms of genes VAV-2-3 in hypertensive subjects.
Methodology: A cross- sectional design we will performed . Population: 486 hypertensive patients. Target organ damage will be assessed by tests recommended in 2013 European guidelines of hypertension. Blood pressure office and ambulatory, retinal caliber vassels,oxidative stress and polymorphisms VAL -2-3 will be measurement.
Read the detailed description
Ambulatory blood pressure monitoring (ABPM): The ABPM will be performed on a day of standard activity, with an adequate cuff for the size of the patient's arm. A control system, SpaceLabs 90207 model (Spacelabs Healthcare, Issaquah, Washington, USA), validated according to the protocol of the British Hypertension Society, will be used [57]. The records in which the percentage of valid readings will be 80% of the total and with valid readings at all times were considered to be valid. Furthermore, for the records to be evaluable, at least 14 measurements will be required during the daytime period, or at least seven during the nightime or rest period. The monitor will be scheduled for obtaining blood pressure measurements every 20 min during the daytime period and every 30 min during the rest period. The average and dispersion estimators of SBP and DBP were calculated during the 24-h, daytime and nightime periods, defined based on the diary reported by the patient. The patient completes a form specifying bedtime and wake-up time.
Ambulatory arterial stiffness index (AASI) and Home arterial stiffness index (HASI): Arterial stiffness will be evaluated by the ambulatory and home arterial stiffness indices (AASI and HASI). For AASI and HASI estimation, the regression slope of diastolic on systolic blood pressure will be computed for each individual on the basis of 24-hour ABPM (AASI) and also HASI readings over 6 days. AASI as well as HASI were defined as one minus the respective regression slope of DBP on SBP [58]. AASI will also computed from waking or sleeping blood pressure.
Evaluation of retinal vessels: Retinography will be performed using a Topcon TRC NW 200 nonmydriatic retinal camera (Topcon Europe B.C., Capelle a/d Ijssel, The Netherlands), obtaining nasal and temporal images centered on the disk. The nasal image with the centered disk will be loaded into the developed software, AV Index calculator (Ciclorisk SL, Salamanca, Spain, registry no. 00/2011/589). The software automatically recognizes the disk and draws two external concentric circles which delimit area A, between 0 and 0.5 disk diameters from the optic disk margin, and area B, between 0.5 and 1 disk diameters from the margin. The software first identifies the limits of the different vessels, after which it automatically recognizes arteries and veins, and makes multiple measurements of the diameter of the section of the vessels circulating through area B. It finally estimates the mean caliber of veins and arteries in mm, and these measurements are summarized as an arteriole-venule ratio, AVIx. An AVIx of 1.0 suggests that arteriolar diameters will be on average the same as venular diameters in that eye, whereas a smaller AVR suggests narrower arterioles. We used the pairs of main vessels in the upper and lower temporal quadrants, rejecting all other vessels, to improve reliability and increase efficiency of the process, analyzing measures for each quadrant separately and together to estimate the mean measure in each eye. [64].
Laboratory:Determining the concentration of superoxide and catecholamines (adrenaline and noradrenaline) in plasma and urine anion will be determined by ELISA (CatCombi ELISA, IBL, Deventer, The Netherlands), following the manufacturers instructions. Superoxide dismutase activity in plasma will be also assessed using ELISA kits (Cu-Zn superoxid-dismutase ELISA, IBL), and the urinary excretion and plasma levels of lipid peroxides by measuring products react with thiobarbituric acid (TBARS) (OxiSelect TBARS Assay Kit, Cell Biolabs, Inc., San Diego, CA 92126).
In a sample of DNA from peripheral blood erythrocyte polymorphisms of VAV and VAV-2-3 genes in all study subjects are studied. To this end, 10cc of venous blood obtained with anticoagulant (EDTA: ethylene diamine tetra-acetic acid).
Renal assessment: The kidney damage will be assessed by measuring creatinine plasma concentration, the glomerular filtration rate was estimated by CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) [59] and the MDRD-IDMS (Modification of Diet in Renal Disease-Isotopic Dilution Mass Spectrometry) [60] equation and proteinuria were assessed by the albumin/creatinine ratio following the 2007 European Society of Hypertension/European Society of Cardiology Guidelines criteria [2]. Subclinical organ damage was defined as plasma creatinine between 1.3 - 1.5 mg/dl in men and 1.2 - 1.4 mg/dl in women, glomerular filtration rate below 60 ml/min or albumin/creatinine ratio > 22 mg/gr in men and 31 mg/ gr in women. Renal disease was defined as plasma creatinine of 1.5 mg/dl or higher in men and 1.4 mg/l in women or albumin/creatinine ratio > 300 mg/24 h.
Cardiac assessment: The electrocardiographic examination will be performed with a General Electric MAC 3.500 ECG System (Niskayuna, New York, USA), that measures automatically the voltage and duration of waves and estimates the criteria of the Cornell voltage-duration product (Cornell VDP) [61] to assess the LVH by the following equation: Men ((RaVL + SV3) * QRS) and women ((RaVL + SV3) * QRS + 6). LVH will be defined as the voltage-duration product > 2,440 mm/ms [2] and Sokolow and R avl > 11.
Pulse wave velocity (PWV): These parameters will be estimated using the SphygmoCor System (AtCor Medical Pty Ltd., Head Office, West Ryde, Australia). Using the SphygmoCor System (Vx pulse wave velocity), and with the patient in the supine position, the pulse waves of the carotid and femoral arteries were analyzed, estimating the delay with respect to the ECG wave and calculating PWV. Distance measurements were taken with a measuring tape from the sternal notch to the carotid and femoral arteries at the sensor location [62].
Assessment of vascular structure by carotid intima media thickness (IMT): Carotid ultrasound to assess C-IMT will be performed by two investigators trained for this purpose before starting the study. The reliability of such recordings was evaluated before the study, using the intraclass correlation coefficient, which showed values of 0.97 (95%CI: 0.94-0.99) for intra-observer agreement on repeated measurements in 20 subjects, and 0.90 (95%CI: 0.74-0.96) for inter-observer agreement. According to the Bland-Altman analysis, the limit of inter-observer agreement was 0.02 (95% CI: -0.05-0.10), while the limit of intra-observer agreement was 0.01 (95% CI: -0.03-0.06). A Sonosite Micromax ultrasound device paired with a 5-10 MHz multi-frequency high-resolution linear transducer with Sonocal software will be used for performing automatic measurements of carotid IMT in order to optimize reproducibility. Measurements will be made of the common carotid after the examination of a 10-mm longitudinal section at a distance of 1 cm from the bifurcation, performing measurements in the anterior or proximal wall, and in the posterior or distal wall in the lateral, anterior and posterior projections, following an axis perpendicular to the artery to discriminate two lines: one for the intima-blood interface and the other for the media-adventitious interface. A total of 6 measurements will be obtained of the right carotid, with another 6 measurements of the left carotid, using average values (average carotid IMT) and maximum values (maximum carotid IMT) automatically calculated by the software [63]. The measurements will be obtained with the subject lying down, with the head extended and slightly turned opposite to the examined carotid artery. The average IMT will considered abnormal if it measured 0.90 mm, or if there will be atherosclerotic plaques with a diameter of 1.5 mm or a focal increase of 0.5 mm or 50% of the adjacent IMT [2].
- Conditions
- Hypertension
- Keywords
- Hypertension, Target organ damage, polymorphism, Hypertensive patients
- Medical subject headings
- Hypertension
What is being measured
The primary outcome is the main question the study is designed to answer.
Target organ damage cardiovascular
Target organ damage, cardiac (left ventricular hypertrophy), Vascular (Pulse wave velocity and Carotid intima media tickness), and renal (Glomerular filtration low and Microalbuminury)
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Dec 2013 (estimated)
- Study startOct 2013
- Primary completionMar 2016
- Study completionMar 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 454 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fundacion para la Investigacion y Formacion en Ciencias de la Salud
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Manuel A Gomez Marcos, MD, Principal investigator, Fundacion Infosalud
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02022618
- Sponsor's protocol ID
- (BIO/SA05/13)
- Acronym
- LOD-HTA
- Status last verified
- Sep 2016
- First submitted
- 10 Dec 2013
- Last updated
- 23 Sep 2016
- Results posted
- No
- Data monitoring committee
- No
Publications
ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013 Oct;31(10):1925-38. doi: 10.1097/HJH.0b013e328364ca4c. No abstract available.
PubMed 24107724Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007 Jan 30;115(4):459-67. doi: 10.1161/CIRCULATIONAHA.106.628875. Epub 2007 Jan 22.
PubMed 17242284Garcia-Ortiz L, Recio-Rodriguez JI, Parra-Sanchez J, Gonzalez Elena LJ, Patino-Alonso MC, Agudo-Conde C, Rodriguez-Sanchez E, Gomez-Marcos MA; Vaso-risk group. A new tool to assess retinal vessel caliber. Reliability and validity of measures and their relationship with cardiovascular risk. J Hypertens. 2012 Apr;30(4):770-7. doi: 10.1097/HJH.0b013e3283506628.
PubMed 22306849Fraser HI, Dendrou CA, Healy B, Rainbow DB, Howlett S, Smink LJ, Gregory S, Steward CA, Todd JA, Peterson LB, Wicker LS. Nonobese diabetic congenic strain analysis of autoimmune diabetes reveals genetic complexity of the Idd18 locus and identifies Vav3 as a candidate gene. J Immunol. 2010 May 1;184(9):5075-84. doi: 10.4049/jimmunol.0903734. Epub 2010 Apr 2.
PubMed 20363978Gomez-Marcos MA, Gonzalez-Sarmiento R, Recio-Rodriguez JI, Agudo-Conde C, Gamella-Pozuelo L, Perretta-Tejedor N, Martinez-Salgado C, Garcia-Ortiz L; Members of the LOD-Hipertension Group. Relationship between target organ damage and blood pressure, retinal vessel calibre, oxidative stress and polymorphisms in VAV-2 and VAV-3 genes in patients with hypertension: a case-control study protocol (LOD-Hipertension). BMJ Open. 2014 Apr 3;4(4):e005112. doi: 10.1136/bmjopen-2014-005112.
PubMed 24699462
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Target Organ Damage and Blood Pressure, Retinal Vessels, Oxidative Stress and Polymorphisms Vav-2 and Vav-3 in Hypertensive Subjects (LOD-Hypertension)
- ClinicalTrials.gov ID
- NCT02022618
- Acronym / sponsor ID
- LOD-HTA / (BIO/SA05/13)
- Conditions
- Hypertension
- Keywords
- Hypertension, Target organ damage, polymorphism, Hypertensive patients
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 454 participants (actual)
- Lead sponsor
- Fundacion para la Investigacion y Formacion en Ciencias de la SaludUniversity, hospital or other
- Study start
- Oct 2013
- Primary completion
- Mar 2016 (actual)
- Study completion
- Mar 2016 (actual)
- First posted
- 30 Dec 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objectives: To analyze the influence on the presence of target organ damage renal, cardiac and vascular of peripheral and central blood pressure, retinal vessels caliber, oxidative stress and polymorphisms of genes VAV-2-3 in hypertensive subjects.
Methodology: A cross- sectional design we will performed . Population: 486 hypertensive patients. Target organ damage will be assessed by tests recommended in 2013 European guidelines of hypertension. Blood pressure office and ambulatory, retinal caliber vassels,oxidative stress and polymorphisms VAL -2-3 will be measurement.
Detailed description
Ambulatory blood pressure monitoring (ABPM): The ABPM will be performed on a day of standard activity, with an adequate cuff for the size of the patient's arm. A control system, SpaceLabs 90207 model (Spacelabs Healthcare, Issaquah, Washington, USA), validated according to the protocol of the British Hypertension Society, will be used [57]. The records in which the percentage of valid readings will be 80% of the total and with valid readings at all times were considered to be valid. Furthermore, for the records to be evaluable, at least 14 measurements will be required during the daytime period, or at least seven during the nightime or rest period. The monitor will be scheduled for obtaining blood pressure measurements every 20 min during the daytime period and every 30 min during the rest period. The average and dispersion estimators of SBP and DBP were calculated during the 24-h, daytime and nightime periods, defined based on the diary reported by the patient. The patient completes a form specifying bedtime and wake-up time.
Ambulatory arterial stiffness index (AASI) and Home arterial stiffness index (HASI): Arterial stiffness will be evaluated by the ambulatory and home arterial stiffness indices (AASI and HASI). For AASI and HASI estimation, the regression slope of diastolic on systolic blood pressure will be computed for each individual on the basis of 24-hour ABPM (AASI) and also HASI readings over 6 days. AASI as well as HASI were defined as one minus the respective regression slope of DBP on SBP [58]. AASI will also computed from waking or sleeping blood pressure.
Evaluation of retinal vessels: Retinography will be performed using a Topcon TRC NW 200 nonmydriatic retinal camera (Topcon Europe B.C., Capelle a/d Ijssel, The Netherlands), obtaining nasal and temporal images centered on the disk. The nasal image with the centered disk will be loaded into the developed software, AV Index calculator (Ciclorisk SL, Salamanca, Spain, registry no. 00/2011/589). The software automatically recognizes the disk and draws two external concentric circles which delimit area A, between 0 and 0.5 disk diameters from the optic disk margin, and area B, between 0.5 and 1 disk diameters from the margin. The software first identifies the limits of the different vessels, after which it automatically recognizes arteries and veins, and makes multiple measurements of the diameter of the section of the vessels circulating through area B. It finally estimates the mean caliber of veins and arteries in mm, and these measurements are summarized as an arteriole-venule ratio, AVIx. An AVIx of 1.0 suggests that arteriolar diameters will be on average the same as venular diameters in that eye, whereas a smaller AVR suggests narrower arterioles. We used the pairs of main vessels in the upper and lower temporal quadrants, rejecting all other vessels, to improve reliability and increase efficiency of the process, analyzing measures for each quadrant separately and together to estimate the mean measure in each eye. [64].
Laboratory:Determining the concentration of superoxide and catecholamines (adrenaline and noradrenaline) in plasma and urine anion will be determined by ELISA (CatCombi ELISA, IBL, Deventer, The Netherlands), following the manufacturers instructions. Superoxide dismutase activity in plasma will be also assessed using ELISA kits (Cu-Zn superoxid-dismutase ELISA, IBL), and the urinary excretion and plasma levels of lipid peroxides by measuring products react with thiobarbituric acid (TBARS) (OxiSelect TBARS Assay Kit, Cell Biolabs, Inc., San Diego, CA 92126).
In a sample of DNA from peripheral blood erythrocyte polymorphisms of VAV and VAV-2-3 genes in all study subjects are studied. To this end, 10cc of venous blood obtained with anticoagulant (EDTA: ethylene diamine tetra-acetic acid).
Renal assessment: The kidney damage will be assessed by measuring creatinine plasma concentration, the glomerular filtration rate was estimated by CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) [59] and the MDRD-IDMS (Modification of Diet in Renal Disease-Isotopic Dilution Mass Spectrometry) [60] equation and proteinuria were assessed by the albumin/creatinine ratio following the 2007 European Society of Hypertension/European Society of Cardiology Guidelines criteria [2]. Subclinical organ damage was defined as plasma creatinine between 1.3 - 1.5 mg/dl in men and 1.2 - 1.4 mg/dl in women, glomerular filtration rate below 60 ml/min or albumin/creatinine ratio > 22 mg/gr in men and 31 mg/ gr in women. Renal disease was defined as plasma creatinine of 1.5 mg/dl or higher in men and 1.4 mg/l in women or albumin/creatinine ratio > 300 mg/24 h.
Cardiac assessment: The electrocardiographic examination will be performed with a General Electric MAC 3.500 ECG System (Niskayuna, New York, USA), that measures automatically the voltage and duration of waves and estimates the criteria of the Cornell voltage-duration product (Cornell VDP) [61] to assess the LVH by the following equation: Men ((RaVL + SV3) * QRS) and women ((RaVL + SV3) * QRS + 6). LVH will be defined as the voltage-duration product > 2,440 mm/ms [2] and Sokolow and R avl > 11.
Pulse wave velocity (PWV): These parameters will be estimated using the SphygmoCor System (AtCor Medical Pty Ltd., Head Office, West Ryde, Australia). Using the SphygmoCor System (Vx pulse wave velocity), and with the patient in the supine position, the pulse waves of the carotid and femoral arteries were analyzed, estimating the delay with respect to the ECG wave and calculating PWV. Distance measurements were taken with a measuring tape from the sternal notch to the carotid and femoral arteries at the sensor location [62].
Assessment of vascular structure by carotid intima media thickness (IMT): Carotid ultrasound to assess C-IMT will be performed by two investigators trained for this purpose before starting the study. The reliability of such recordings was evaluated before the study, using the intraclass correlation coefficient, which showed values of 0.97 (95%CI: 0.94-0.99) for intra-observer agreement on repeated measurements in 20 subjects, and 0.90 (95%CI: 0.74-0.96) for inter-observer agreement. According to the Bland-Altman analysis, the limit of inter-observer agreement was 0.02 (95% CI: -0.05-0.10), while the limit of intra-observer agreement was 0.01 (95% CI: -0.03-0.06). A Sonosite Micromax ultrasound device paired with a 5-10 MHz multi-frequency high-resolution linear transducer with Sonocal software will be used for performing automatic measurements of carotid IMT in order to optimize reproducibility. Measurements will be made of the common carotid after the examination of a 10-mm longitudinal section at a distance of 1 cm from the bifurcation, performing measurements in the anterior or proximal wall, and in the posterior or distal wall in the lateral, anterior and posterior projections, following an axis perpendicular to the artery to discriminate two lines: one for the intima-blood interface and the other for the media-adventitious interface. A total of 6 measurements will be obtained of the right carotid, with another 6 measurements of the left carotid, using average values (average carotid IMT) and maximum values (maximum carotid IMT) automatically calculated by the software [63]. The measurements will be obtained with the subject lying down, with the head extended and slightly turned opposite to the examined carotid artery. The average IMT will considered abnormal if it measured 0.90 mm, or if there will be atherosclerotic plaques with a diameter of 1.5 mm or a focal increase of 0.5 mm or 50% of the adjacent IMT [2].
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 20 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Population: 486 hypertensive patients (20-80 years) will be assessed with all tests recommended in 2013 European guidelines of hypertension
Key inclusion criteria (1 listed)
- Subjects diagnosed of essential hypertension and age between 20-80 years.
Key exclusion criteria (1 listed)
- Participants who do not sign the consent written informed
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Target organ damage cardiovascular
Time frame: 1 year
Target organ damage, cardiac (left ventricular hypertrophy), Vascular (Pulse wave velocity and Carotid intima media tickness), and renal (Glomerular filtration low and Microalbuminury)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2016.
- Background: PubMed 24107724ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013 Oct;31(10):1925-38. doi: 10.1097/HJH.0b013e328364ca4c. No abstract available.
- Background: PubMed 17242284Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007 Jan 30;115(4):459-67. doi: 10.1161/CIRCULATIONAHA.106.628875. Epub 2007 Jan 22.
- Background: PubMed 22306849Garcia-Ortiz L, Recio-Rodriguez JI, Parra-Sanchez J, Gonzalez Elena LJ, Patino-Alonso MC, Agudo-Conde C, Rodriguez-Sanchez E, Gomez-Marcos MA; Vaso-risk group. A new tool to assess retinal vessel caliber. Reliability and validity of measures and their relationship with cardiovascular risk. J Hypertens. 2012 Apr;30(4):770-7. doi: 10.1097/HJH.0b013e3283506628.
- Background: PubMed 20363978Fraser HI, Dendrou CA, Healy B, Rainbow DB, Howlett S, Smink LJ, Gregory S, Steward CA, Todd JA, Peterson LB, Wicker LS. Nonobese diabetic congenic strain analysis of autoimmune diabetes reveals genetic complexity of the Idd18 locus and identifies Vav3 as a candidate gene. J Immunol. 2010 May 1;184(9):5075-84. doi: 10.4049/jimmunol.0903734. Epub 2010 Apr 2.
- Derived from this study: PubMed 24699462Gomez-Marcos MA, Gonzalez-Sarmiento R, Recio-Rodriguez JI, Agudo-Conde C, Gamella-Pozuelo L, Perretta-Tejedor N, Martinez-Salgado C, Garcia-Ortiz L; Members of the LOD-Hipertension Group. Relationship between target organ damage and blood pressure, retinal vessel calibre, oxidative stress and polymorphisms in VAV-2 and VAV-3 genes in patients with hypertension: a case-control study protocol (LOD-Hipertension). BMJ Open. 2014 Apr 3;4(4):e005112. doi: 10.1136/bmjopen-2014-005112.
Related trials for Hypertension
Not yet recruiting
PAUL® Glaucoma Implant Safety and Effectiveness Study
Refractory Glaucoma
RecruitingObservational study
Asthma and Primary Arterial Hypertension: an Inflammatory Link?
Asthma Bronchial
RecruitingObservational study
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Intracerebral Hemorrhage, Stroke
RecruitingPhase 1/2
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Recruiting
Dry Weight Reduction Intervention Via Extra Ultrafiltration
Fluid Accumulation, Blood Pressure Management
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Manuel A Gomez Marcos, MD principal investigator
Fundacion Infosalud
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypertension, run by Fundacion para la Investigacion y Formacion en Ciencias de la Salud at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Target organ damage cardiovascular (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02022618, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2016.